Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 191

The DOI matches its Crossref record.

Prospective Study of High-Dose Cabergoline Treatment of Prolactinomas in 150 Patients

Ono, Masami, Miki, Nobuhiro, Kawamata, Takakazu, Makino, Rena, Amano, Kosaku, Seki, Toshiro, Kubo, Osami, Hori, Tomokatsu, Takano, Kazue · 2008 · The Journal of Clinical Endocrinology & Metabolism

Abstract

Context: Cabergoline fails to normalize hyperprolactinemia in a considerable proportion of prolactinomas, especially macroadenomas. Objective: We examined the effect of individualized high-dose cabergoline treatment on hyperprolactinemia in prolactinomas. Patients: The study included 122 women and 28 men (93 microadenomas and 57 macroadenomas). Forty-seven had undergone transsphenoidal surgery. According to the preceding medical treatment, the participants were separated into untreated (group U; n = 60), intolerant (group I; n = 64), and resistant (group R; n = 26) groups. Interventions: We promptly increased cabergoline dose on the basis of individual prolactin levels. Length of treatment was 1 yr. Results: Cabergoline normalized hyperprolactinemia in all patients except one. The proportion of prolactin normalization in both groups U and I was 83% at 3 months and 95% at 6 months. By contrast, that in group R was 35% at 3 months and 58% at 6 months. Mean cabergoline dose in milligrams per week at the time of prolactin normalization was 2.0 ± 0.3 in group U, 0.9 ± 0.1 in group I, and 5.2 ± 0.6 in group R. Prolactin normalization rate at the 3 mg/wk dose was 84% overall but only 35% in group R. Serum progesterone or testosterone levels, diminished in 122 women or 16 men, respectively, were recovered in all except one resistant and four postmenopausal or panhypopituitary patients. Conclusion: Individualized high-dose cabergoline treatment can normalize hyperprolactinemia and hypogonadism in nearly all prolactinomas irrespective of tumor size or preceding treatments. Hyperprolactinemia could be controlled in poor responders within 1 yr with doses higher than 3 mg/wk.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2007-2758

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 191

Metadata

Authors
Ono, M., Miki, N., Kawamata, T., Makino, R., Amano, K., Seki, T., Kubo, O., Hori, T., & Takano, K.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2008-12-01
Volume
93
Issue
12
Pages
4721-4727
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W1963579017
Cited by
191
References
0
FWCI
5.88
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prospective Study of High-Dose Cabergoline Treatment of Prolactinomas in 150 Patients. https://app.cochat.ai/papers/10.1210/jc.2007-2758
The paper
Ono, M., Miki, N., Kawamata, T., Makino, R., Amano, K., Seki, T., Kubo, O., Hori, T., & Takano, K. (2008). Prospective Study of High-Dose Cabergoline Treatment of Prolactinomas in 150 Patients. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2007-2758

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.